In European observational studies, Tygacil demonstrated high clinical response rates in 785 adult patients with cIAI from four different countries (France, Italy, Spain and Germany).1
Most patients with cIAI were critically ill1
Many required ICU care at the time of treatment administration and had clinical factors known to be associated with failure of cIAI treatment – High APACHE II scores, advanced age, comorbidity involving organ dysfunction
Clinical response at end of treatment in patients with cIAI1
Clinical response rates were 80.6% (329/408) in patients treated with Tygacil monotherapy and 73.2% (238/325) in patients treated with combination therapy – Overall, 54.8% of patients received Tygacil as monotherapy and 45.2% as combination therapy
No difference was observed overall in clinical response for patients who received Tygacil as first-or second-line therapy (76.2% vs 76.7%, respectively)
Community-and hospital-acquired infections were associated with response rates of 81.6% and 75.2%, respectively
Clinical response at the end of treatment by disease severity1
Tygacil alone or in combination has a safety profile consistent with the level of critical illness in cIAI as shown in real-life data from European observational non comparative studies.
View complicated intra-abdominal infections (cIAI) clinical data
APACHE, Acute Physiology and Chronic Health Evaluation; CI, confidence interval; cIAI, complicated intra-abdominal infection; cSSTI, complicated skin and soft tissue infection; mITT, modified intention-to-treat; SOFA, Sequential Organ Failure Assessment, TOC, test of cure.
- Eckmann C, Montravers P, Bassetti M, et al. Efficacy of tigecycline for the treatment of complicated intra-abdominal infections in real-life clinical practice from five European observational studies. J Antimicrob Chemother. 2013;68 (suppl2):ii25–ii35.
- Guirao X, Sanchez Garcia M, Bassetti M, et al. Safety and tolerability of tigecycline for the treatment of complicated skin and soft-tissue and intra-abdominal infections: an analysis based on five European observational studies. J Antimicrob Chemother. 2013;68 (suppl2):ii37–ii44.